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Abstract Despite continuous efforts for an optimal ste-
roid replacement, recent observations suggest increased
cardiometabolic risk and related mortality in primary
adrenal insufficiency (PAI). Adipokines are peptides from
the adipose tissue, markers of cardiometabolic dysfunction.
This study was aimed to evaluate serum levels of adipo-
kines: leptin, adiponectin, and resistin in PAI during con-
ventional steroid substitution. The analysis comprised 63
patients (mean age 42.7 ± 14.1 years) and 63 healthy
controls. Serum adipokines, lipid profile, and plasma glu-
cose were assessed in both cohorts. ACTH, serum insulin,
HOMA-IR, DHEA-S, cortisol and 24 h urinary free corti-
sol were determined in PAI. Body mass composition was
analyzed by Dual-Energy X-ray Absorptiometry. Mean
BMI in the control group was 24.1 ± 3.9 kg/m2 and
23.7 ± 3.9 kg/m2 in the PAI cohort. Serum leptin and
adiponectin levels were similar in both groups, whereas
resistin appeared significantly lower among affected sub-
jects (p = 0.0002). Its levels were weakly correlated with
HOMA-IR (p = 0.048). Leptin was independently corre-
lated with fasting insulin, HOMA-IR, BMI, and body fat
(p \ 0.001). At the multiple regression analysis only
weight (p = 0.017), total and HDL cholesterol (p \ 0.001)
appeared significant predictors of adiponectin level. No
adipokine correlations with serum cortisol or daily hydro-
cortisone dose were found. Patients receiving DHEA sub-
stitution displayed lower leptin and adiponectin levels
(p \ 0.05). In conclusion, our study did not provide evi-
dence of an adverse adipokine profile in patients with PAI
under conventional glucocorticoid replacement. Serum
adipokines in treated PAI follow similar correlations to
those reported in healthy subjects. Further prospective
studies are warranted to verify and explain plausible excess
of cardiovascular mortality in PAI.
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Introduction
Primary adrenal insufficiency (PAI), also known as Addi-
son’s disease, is traditionally accounted among rare dis-
orders. Nonetheless, recent epidemiological data from the
developed countries indicate that its prevalence may
exceed 100 cases per million, and a considerable rise in
autoimmune etiology is currently noted [1]. PAI treatment
relies upon exogenous steroid substitution; however, stan-
dard oral replacement schemes fail to perfectly mimic the
natural circadian rhythm of cortisol secretion [2]. Optimi-
zation of the individual hormone dosage and long-term
monitoring remain major clinical challenges. In case of
insufficient glucocorticoid substitution patients are threa-
tened by potentially lethal adrenal crisis, while chronic
over-replacement may lead to adverse effects, such as
glucose intolerance, enhanced visceral adiposity, and bone
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demineralisation [3]. Former reports substantiated normal
life expectancy in properly diagnosed subjects with PAI [4,
5], while recently published observations suggest that
increased death rates persist for many years after diagnosis
[6–8]. Excess mortality in PAI is due to infection, trauma
and other common causes of the adrenal crisis [6] but
unexpectedly might also be connected with cardiovascular
diseases and malignancies [7, 8]. Although no unequivocal
evidence of increased cardiovascular morbidity was dem-
onstrated to date, elevated incidence of cardiometabolic
risk factors, including abdominal obesity, dyslipidemia,
and impaired glucose tolerance was reported in PAI [3, 9,
10]. These features, hallmarks of the metabolic syndrome,
might possibly be accounted for by superfluous glucocor-
ticoid treatment.
Recent studies reveal that altered serum levels of adi-
pokines, such as leptin, adiponectin, and resistin, may
reflect increased cardiometabolic risk [11–14]. Adipokines
are biologically active peptides, which originate from the
adipose tissue. In the auto-, para- and endocrine manner,
they affect and integrate the energetic balance, food intake,
glucose and lipid metabolism. Leptin was one of the first
known adipose tissue hormones [15]. It acts as central
lipostatic signal, limiting the food ingestion and increasing
the energy expenditure [16, 17]. Leptin is mainly synthe-
sized by the subcutaneous adipose tissue and its plasma
levels increase with the weight gain, suggesting that
common human obesity is a leptin-resistant state [15].
Apart from overfeeding, leptin secretion is stimulated by
insulin, glucocorticoids, TNFa, and estrogens [18]. Leptin
replacement in patients homozygous for its gene mutations
and in subjects with lipodystrophy syndromes who exhibit
reduced leptin levels, results in beneficial effects on body
mass composition, improved lipid profile and glucose
metabolism [19].
Adiponectin is exclusively produced by adipocytes,
especially in subcutaneous fat, but in contrast to leptin, its
synthesis declines in obese subjects [20]. Adiponectin
release in vitro is triggered by insulin and PPARc agonists,
and suppressed by TNFa, glucocorticoids, and androgens
[21]. Its receptors are mainly located in muscle and liver,
where adiponectin stimulates oxidation of the fatty acids,
inhibits hepatic gluconeogenesis and improves insulin
sensitivity [22]. Adiponectin presents anti-inflammatory
and anti-atherogenic action, decreasing the synthesis of
endothelial adhesion molecules, foam cell generation, and
smooth muscle proliferation [11, 22]. Adiponectin defi-
ciency is connected with insulin resistance, impaired glu-
cose tolerance, hyperlipidemia, and high risk of
cardiovascular disease [11, 21, 23].
Resistin was named by its ability to induce insulin
resistance [24]. Its expression prevails in visceral adipose
tissue, and may be stimulated by feeding, glucose,
dexamethasone and androgens [25]. In rodent models,
resistin impairs insulin action and glucose tolerance [24]. It
up-regulates hepatic gluconeogenesis enzymes and reduces
the expression of insulin receptor substrate-2, a cytoplas-
mic adaptor that mediates downstream insulin effects [25,
26]. Presumably resistin might represent a link between
obesity, insulin resistance and diabetes. However, meta-
bolic relevance of human resistin remains ambiguous. The
protein shares only 60 % amino acid identity with its
rodent homologue, its expression seems to prevail in
macrophages and is differently regulated [25, 27]. Data
correlating circulating resistin with human obesity and
insulin resistance are contradictory [28, 29]. Nonetheless,
resistin displays adverse vascular effects, comprising
increased expression of vascular adhesion molecules and
proinflammatory cytokines, together with enhanced smooth
muscle proliferation [12].
Broadly, adipokines appear markers of metabolic and
cardiovascular pathology and their serum levels may
indicate elevated disease risk [11–13, 20, 30]. Therefore, it
seemed of interest to investigate circulating adipokines in a
population with primary adrenal failure, suspected to be at
particular risk for cardiometabolic morbidity and mortality.
The current analysis was designed to evaluate serum levels
of leptin, adiponectin, and resistin in a series of PAI
patients during conventional steroid replacement therapy,
and to investigate their correlation with clinical, bio-
chemical and hormonal parameters, which may be con-
nected with cardiometabolic dysfunction.
Materials and methods
The study comprised 63 patients (41 females and 22 males)
with PAI of autoimmune etiology and 63 healthy sex-, age-
and BMI-matched control subjects, all issued from Polish
population of Caucasian descent. The mean age of affected
individuals was 42.7 ± 14.1 years and mean duration of
glucocorticoid replacement was 11.0 ± 10.4 years (range
1–45 years). The diagnosis of PAI was based on typical
signs and symptoms (weakness and fatigue, hypotension
and postural symptoms, anorexia, weight loss, nausea/
vomiting, salt-craving, hyperpigmentation of skin and
mucosae), basal serum cortisol levels below 83 nmol/l
(3 lg/dl), accompanied by plasma ACTH exceeding
22 pmol/l (100 pg/ml), and corroborated by lack of
response of the adrenal cortex to intravenous stimulation
with synthetic ACTH1–24 (peak serum cortisol less than
500 nmol/l = 18 lg/dl) [1]. Autoimmune origin of the
disease was confirmed with positive serum autoantibodies
to 21-hydroxylase evaluated using RIA assay (RSR Ltd,
Cardiff, UK). Daily hydrocortisone (HC) dose ranged
between 7.5 and 35 mg/d (mean 24.1 ± 5.8 mg/d), and for
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the purpose of the study was corrected for the body weight
in kilograms (mean dosage 0.36 ± 0.10 mg/kg). Forty-one
(65 %) patients were on twice daily regimen, and the
remaining subjects were taking HC three times per day.
The majority of patients (81 %) received mineralocorticoid
replacement with daily fludrocortisone (0.05–0.1 mg) to
normalize blood pressure (BP) and serum electrolytes.
Additionally 19 of them have been treated with 10–25 mg
of dehydroepiandrosterone (DHEA) per day for at least
6 months before the analysis. At the time of the study all
patients were either euthyroid or on stable levothyroxine
replacement conferring TSH and thyroid hormone levels
within the reference range. Individuals with known coex-
isting diabetes were excluded. Patients were enrolled from
the inpatient and outpatient endocrine clinics at Poznan´
University of Medical Sciences. The control group was
recruited among blood donors from the Regional Blood
Transfusion Centre in Poznan´. Their mean age was
42.8 ± 12.7 years. None of them was taking any medica-
tion interfering with the hypothalamo-pituitary-adrenal
axis. Informed consent was obtained from all participants,
and the study was approved by the local ethical committee
at Poznan´ University of Medical Sciences.
Clinical evaluation of study participants comprised
weight, height, and BP measurements at noon (mean of
three independent measurements on consecutive days).
Blood samples were drawn in the morning after overnight
fast. Serum adipokines were evaluated in all participants
using commercially available kits based on radioimmuno-
assay techniques. Leptin levels were assessed by means of
Human Leptin RIA-CT (DIAsource ImmunoAssays S.A.,
Nivelles, Belgium), with the intra- and interassay coeffi-
cients of variation (CV) 4.8 and 5.3 %, respectively.
Adiponectin was analyzed with Human Adiponectin RIA
Kit (Millipore, MA, USA) featuring the respective intra-
and interassay CVs 6.2 and 9.2 %. Serum resistin con-
centration was evaluated using Resistin (43–65) (Human)
RIA Kit (Phoenix Pharmaceuticals, CA, USA), with the
detection limit 153.3 pg/ml. Serum DHEA sulfate (DHEA-
S), insulin, cortisol and 24 h urinary free cortisol (UFC)
excretion were determined in affected subjects by electr-
ochemiluminescent method (ECLIA) using Modular Ana-
lytics E170 and commercial kits from Roche Diagnostics.
Plasma ACTH was assessed in PAI patients by IRMA
(Brahms GmBH, Hennigsdorf, Germany). Other laboratory
analyses comprised fasting plasma glucose, triglyceride,
total cholesterol and its high-density lipoprotein (HDL)
fraction and were performed in all subjects (except for
tryglicerides in controls) by standard laboratory methods
applied in our tertiary centre. BMI was calculated as
weight (kg)/height (m) squared. Low-density lipoprotein
(LDL) cholesterol was determined by Friedewald’s for-
mula. Insulin resistance was studied using the homeostasis
model assessment of insulin resistance (HOMA-IR) cal-
culated by the formula: fasting serum insulin (lU/
ml) 9 fasting serum glucose (mmol/l)/22.5.
Moreover, body mass composition was analyzed in 39
patients with PAI by Dual-Energy X-ray Absorptiometry
method (Lunar DPX; Lunar Corp. Madison, WI).
Statistical analyses were performed by means of
GraphPad Prism v.6.0 software (La Jolla, CA, USA). Data
are presented as mean ± standard deviation (±SD) unless
stated otherwise. Normally distributed data were compared
using unpaired Student t test, whereas those with non-
normal distribution were analyzed by nonparametric
Mann–Whitney test. Statistical correlations were assessed
by calculation of Pearson’s or Spearman’s coefficient,
depending on data distribution. Multivariate linear regres-
sion was applied to test for independent relationship of
parameters, which displayed significant correlations in
univariate model. Two-tailed p values \0.05 were con-
sidered statistically significant.
Results
Mean BMI value in the control group was 24.1 ± 3.9 kg/
m2 and 23.7 ± 3.9 kg/m2 in the PAI cohort. Considering
the WHO classification of the body mass according to the
BMI value, 4 (6.3 %) PAI patients were underweight, 41
(65.2 %) presented normal weight, 14 (22.2 %) were
overweight, and 4 (6.3 %) obese. Body mass composition
demonstrated mean 29.9 ± 11.2 % body fat proportion and
28.4 ± 11.2 % trunk fat content among PAI patients.
Blood pressure measurements revealed mean systolic BP
118 ± 13 mmHg and mean diastolic BP 76 ± 7 mmHg in
the studied PAI group. As expected, serum cortisol levels
in healthy subjects were considerably higher than in PAI
patients (417.8 ± 169.1 vs. 36.5 ± 42.5; p \ 0.001). Only
limited biochemical analyses were performed in the control
group; however, no significant differences were found for
the fasting glucose and cholesterol fractions compared to
the PAI cohort (Table 1).
Serum adipokine evaluation revealed that leptin levels
in PAI cohort were comparable to healthy controls
(12.0 ± 11.8 vs. 11.1 ± 8.5 ng/ml; p = 0.749) (Fig. 1a)
and higher in females compared to males (p \ 0.001 in
both healthy and affected subjects). Leptin concentration in
PAI did not correlate with age and serum cortisol
(p [ 0.05) although these correlations were present in the
control group (r = 0.43, p \ 0.001 and r = 0.34,
p = 0.016, respectively). In PAI cohort leptin was corre-
lated with serum DHEA-S (r = -0.47, p \ 0.001), HDL
cholesterol (r = 0.34, p = 0.006), fasting insulin (r =
0.57, p \ 0.001) and HOMA-IR (r = 0.56, p \ 0.001). It
also revealed positive correlation with BMI (r = 0.26,
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p = 0.04) and with fat proportion in whole body (r = 0.74,
p \ 0.001) and trunk (r = 0.68, p \ 0.001). No correlation
between leptinemia and disease duration, daily HC dose,
24 h urinary free cortisol, ACTH, total cholesterol and
triglycerides was detected. Parameters displaying signifi-
cant correlation with leptin level were tested in multivari-
ate analyses for independent associations. Circulating
leptin in PAI appeared independently correlated with
fasting insulin and HOMA-IR, BMI, and the proportion of
total and trunk body fat (all p \ 0.001). Correlation ana-
lysis in control subjects confirmed well-known relationship
between leptin and BMI (r = 0.31, p = 0.009) but did not
provide evidence for a link between leptin and cholesterol
profile (p [ 0.05).
Circulating adiponectin levels in PAI subjects were also
similar to controls (7.90 ± 4.31 vs. 6.88 ± 3.28 lg/ml,
p = 0.389) (Fig. 1b). In both groups adiponectin was sig-
nificantly higher among females than in males (p \ 0.001
in PAI and p = 0.002 in controls). There were negative
adiponectin correlations with weight (r = -0.30,
p = 0.019), BMI (r = -0.23, p = 0.025), HOMA-IR
(r = -0.352, p = 0.002) and serum DHEA-S (r = -0.33,
p = 0.009) among PAI subjects. Positive correlations with
total cholesterol (r = 0.44, p \ 0.001) and its HDL frac-
tion (r = 0.50, p \ 0.001) were also found. Only a bor-
derline negative correlation with the proportion of whole
body fat (r = -0.14, p = 0.056) was detected, whereas no
relationship with the trunk fat, PAI duration, daily HC
dose, plasma ACTH, serum cortisol, LDL cholesterol, tri-
glyceride concentration or 24 h UFC excretion was dis-
covered (p [ 0.05). At multiple regression analysis only
weight (p = 0.017), total and HDL cholesterol
(p = 0.0025 and p = 0.0003, respectively) remained sig-
nificant predictors of adiponectinemia in PAI. Similar
adiponectin correlations appeared significant in the control
Table 1 Biochemical and
hormonal findings in patients
with primary adrenal
insufficiency (PAI) and healthy
controls
Statistically significant value is
given in bold
NA non-assessed, UFC urinary
free cortisol
Unit PAI patients (n = 63) Healthy controls (n = 63) p value
Mean ± SD Range Mean ± SD Range
Fasting glucose (mmol/l) 4.7 ± 0.7 3.4–6.2 4.8 ± 0.7 3.2–6.8 0.257
Fasting insulin (mU/l) 8.8 ± 6.6 2.6–32.6 NA
HOMA-IR 1.9 ± 1.7 0.4–7.6 NA
Total cholesterol (mmol/l) 5.4 ± 1.3 2.8–9.0 5.2 ± 1.1 2.9–8.1 0.601
HDL (mmol/l) 1.7 ± 0.5 0.9–3.1 1.6 ± 0.5 0.9–2.8 0.457
LDL (mmol/l) 3.0 ± 1.1 0.9–6.0 2.9 ± 1.0 1.1–5.3 0.582
Triglycerides (mmol/l) 1.4 ± 0.7 0.4–3.9 NA
ACTH (pg/ml) 434 ± 444 18–1569 NA
Cortisol (nmol/l) 36.5 ± 42.5 0–163.6 417.8 ± 169.1 155.3–721.5 <0.001
DHEA-S (lg/dl) 64.4 ± 97.9 0.1–209.6 NA




Fig. 1 Serum adipokine levels in patients with primary adrenal
insufficiency (PAI) and healthy control subjects (CON): a serum
leptin, b serum adiponectin, c serum resistin
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group: weight (r = -0.33, p = 0.007), BMI (r = -0.29,
p = 0.012), and HDL cholesterol (r = 0.43, p \ 0.001).
Serum resistin was significantly decreased in PAI
patients compared to healthy controls (982 ± 386 vs.
1169 ± 286 pg/ml, p = 0.0002) (Fig. 1c) and did not
differ between females and males. Resistin levels in PAI
were weakly correlated with HOMA-IR (r = 0.14,
p = 0.048) and independent of athropometric, other bio-
chemical and hormonal parameters (p [ 0.05). Likewise,
no statistically significant correlation was found between
circulating resistin and BMI, fasting glucose or cholesterol
profile in controls (p [ 0.05).
Predictably, patients receiving DHEA replacement dis-
played significantly higher serum DHEA-S levels com-
pared to those without supplementation of adrenal
androgens (Table 2). These circumstances allowed evalu-
ating the effect of androgens on adipokine levels. In line
with the correlation analyses, patients on DHEA treatment
presented significantly lower leptin (p = 0.040) and
adiponectin (p = 0.017) levels compared to those without
supplementation of adrenal androgens (Table 2). On the
contrary, no effect of DHEA on circulating resistin was
noted (p = 0.664).
Discussion
The rationale for our investigation was based upon
numerous former studies indicating that glucocorticoids
influence adipokine synthesis. Glucocorticoids stimulate
leptin production in cultured rat and human adipocytes [31,
32] and may enhance insulin-induced leptin release in vitro
and in vivo [32, 33]. In humans, most studies support a
positive correlation between serum cortisol and leptin
concentrations, as demonstrated in our control cohort [34].
Subjects with Cushing disease display consistently elevated
leptin levels, which tend to gradually decrease after treat-
ment [35, 36]. High dose, synthetic steroids, dexametha-
sone and prednisone, produce similar effect of leptin rise
[33, 34, 37]. Accordingly, inhibition of adrenal cortisol
synthesis with metyrapone induces a significant decrease in
leptin secretion [38]. Nevertheless, a study assessing
various 24 h HC infusion regimens revealed that short-term
changes in circulating cortisol, which remained within the
physiological range, did not affect leptin levels [39]. This
would be in agreement with our finding that serum leptin in
PAI appeared similar to healthy controls. In contrast to
leptin, previous investigations of the relationship between
adiponectin and glucocorticoids provided inconsistent
results. In vitro studies indicate that glucocorticoids inhibit
adiponectin secretion in humans and mice [40, 41]. In vivo
analyses demonstrated positive as well as negative corre-
lation between serum adiponectin and cortisol, which has
not been elucidated even when free cortisol index or glu-
cocorticoid bioactivity was considered [37, 42–44].
Diminished adiponectin levels were found in Cushing’s
syndrome, although successful treatment not always leads
to rise in adiponectinemia [35, 45]. In our study adipo-
nectin levels did not differ between healthy and PAI indi-
viduals, suggesting that conventional steroid replacement
does not affect adiponectin secretion. In line, daily HC
dose, serum cortisol level, nor UFC excretion were corre-
lated with adiponectin in PAI patients. Finally, according
to the results of in vitro experiments, a positive relationship
between resistin and cortisol could be presumed, corre-
sponding to the supposition that resistin was involved in
glucocorticoid-induced insulin resistance [46]. Elevated
resistin levels were found in patients with Cushing’s syn-
drome; however, a curative surgery did not influence res-
istin concentration despite a fall in UFC and improved
insulin sensitivity [35]. Increased serum resistin was also
reported in subjects with adrenal incidentalomas displaying
subclinical hypercortisolaemia [47]. However, short-term
dexamethasone administration, which enhanced insulin
resistance, did not alter circulating resistin levels in obese
subjects [48]. In our study no correlation was detected
between serum cortisol and resistin, therefore observed
decrease in circulating resistin in PAI could not be
explained by steroid deficiency.
Conventional oral glucocorticoid substitution implies
intervals of supra-physiological cortisol levels hence it
always raises concerns about possible adverse effects of
long-term over-treatment [1–3]. Although far from perfect,
this therapy does not seem to induce changes in circulating
Table 2 Serum dehydroepiandrosterone sulfate (DHEA-S) and adipokine levels in patients with primary adrenal insufficiency receiving
dehydroepiandrosterone replacement (on DHEA) and those without DHEA treatment (no DHEA)
Unit On DHEA (n = 19) No DHEA (n = 44) p value
Mean ± SD Range Mean ± SD Range
DHEA-S (lg/dl) 221.7 ± 133.9 77.2–503.0 13.5 ± 20.2 0.1–74.7 <0.001
Leptin (ng/ml) 8.3 ± 9.9 0.3–43.2 17.1 ± 16.6 0–60.1 0.040
Adiponectin (lg/ml) 6.1 ± 3.8 0.8–15.6 8.7 ± 4.3 2.5–19.4 0.017
Resistin (pg/ml) 942 ± 273 429–1416 999 ± 428 258–2558 0.664
Statistically significant values are given in bold
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adipokines, which might be indicative of steroid excess. In
our study leptin and adiponectin levels remained similar to
healthy controls, matched for age, gender and BMI. More-
over, healthy and affected subjects presented no differences
in fasting glucose and cholesterol profiles, both features
involved in cardiometabolic risk. Mean (±SD) HOMA-IR in
PAI patients (1.9 ± 1.7) does not support common insulin
resistance, however, relatively high standard deviation value
indicates that some of these subjects may exhibit impaired
insulin sensitivity. Unfortunately, there is a great variability
in the HOMA-IR thresholds in different populations there-
fore lack of data from our control cohort impairs accurate
interpretation of these findings [49].
Recent reports from Sweden suggest increased cardio-
vascular morbidity and mortality in primary adrenal failure
due to ischemic heart disease and cerebrovascular stroke
[7, 8, 50]. Their authors postulate plausible role of inade-
quate steroid replacement. Glucocorticoids, which are
known for their impact on cardiovascular system, may
promote hypertension, visceral obesity, hyperglycemia and
dyslipidemia [51]. Indeed, higher frequencies of these
cardiovascular risk factors were demonstrated in PAI [3, 9,
10]. However, mean glycemic and lipid parameters were
similar in Italian patients and controls [9]. A comparison
between South African and Swedish PAI cohorts revealed
significant population differences, with the Scandinavian
results comprised within the reference range [52]. More-
over, lipid profiles evaluated in a large cohort of British
patients on the occasion of a DHEA trial also appeared
normal [53]. Unfortunately, the number of clinical studies
addressing cardiovascular risk under glucocorticoid sub-
stitution remains limited. Swedish data, which support
increased incidence of cardiovascular deaths in PAI, were
derived from the national hospital and death registers [7,
8]. Health registers, even very meticulous, may be biased
by variable local criteria of diagnosis and administrative
reporting errors. Therefore, designed clinical studies seem
a more reliable source of information. In a retrospective
Norwegian study comprising the entire PAI population,
cardiovascular disease appeared the most common cause of
mortality, accounting for 39 % of deaths, but this value
remained comparable to the general population [6]. On the
whole, at present there is no definitive proof of increased
cardiovascular morbidity and mortality among patients
with PAI. Furthermore, our analysis of their serum adipo-
kine profile did not reveal patterns typical for cardiomet-
abolic disease and no correlation between circulating
cortisol or HC dose and adipokine level was found. How-
ever, large prospective studies are still warranted to clearly
establish if subjects receiving standard glucocorticoid
substitution are at exacerbated cardiometabolic risk.
Correlations between circulating adipokines and
anthropometric parameters in patients with PAI in our
study were in keeping with previous findings from different
lean and obese cohorts. Leptin levels appeared positively
correlated with BMI and fat proportion, whereas an inverse
relationship was confirmed for adiponectin and weight in
PAI and healthy subjects [14, 18, 39, 45, 54]. HDL cho-
lesterol emerged as a significant positive predictor of
adiponectin level in both groups [14], which is in line with
a favorable cardiometabolic profile associated with higher
adiponectin concentration [45, 54, 55]. Finally, insulin
resistance marker, HOMA-IR, revealed a positive correla-
tion with leptin and a negative correlation with adiponectin
level, although the latter disappeared in multiple regression
analysis. Both correlations were formerly reported in sev-
eral populations [39, 42, 45, 54, 55]. Leptinemia was even
suggested to be a more robust surrogate marker of insulin
sensitivity than fasting insulin [56]. Additionally, our
analysis supports the relationship between resistin level
and insulin resistance, even though this correlation was
borderline and studied only in PAI cohort. Former data
from humans remain elusive; however, some studies in
healthy lean adults confirm resistin correlation with fasting
insulin and HOMA-IR [39, 54].
Interestingly, both leptin and adiponectin revealed nega-
tively correlated with DHEA-S levels in our PAI cohort.
Similar relationship between leptin and DHEA-S was
reported in hypoadrenal women receiving DHEA replace-
ment, despite lack of change in BMI and body composition
over the 4 months treatment period [57]. Moreover, leptin-
lowering effect of androgen substitution was reported in
hypogonadal men [58]. Inverse adiponectin correlation with
adrenal androgen was previously described in congenital
adrenal hyperplasia and polycystic ovaries syndrome [59,
60]. In our study, these correlations were lost in multiple
regression analysis but prompted a post hoc analysis com-
paring adipokine levels in patients receiving DHEA substi-
tution and those who were not under adrenal androgen
replacement. Accordingly, leptin and adiponectin appeared
significantly higher in non-substituted subjects (Table 2).
These observations are in line with in vitro data, which
confirm suppressive effect of androgens on leptin and
adiponectin synthesis [18, 21]. In vivo, lower androgen
levels may contribute to sexual dimorphism of circulating
adipokine levels, which was also demonstrated in our healthy
and affected cohorts [39, 54, 55, 61]. These results add up to
the current discussion concerning metabolic benefits of the
DHEA replacement in adrenal failure, which remain con-
troversial despite several randomized trials [53, 62, 63].
To summarize, our study did not provide evidence of an
adverse adipokine profile in patients with PAI under con-
ventional glucocorticoid replacement. The adipokine levels
in treated PAI individuals do not differ from the general
population, and they follow similar correlations to those
reported in healthy subjects. DHEA replacement may
682 Endocrine (2015) 48:677–685
123
decrease serum leptin and adiponectin levels, but clinical
relevance of this finding remains to be elucidated. Further
studies are required to substantiate the epidemiological
observations of increased cardiometabolic morbidity and
mortality in PAI and to explore their pathomechanisms.
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